Dual gold nanostructure-based electrochemical immunosensor for CA125 detection
- 27 Downloads
With an aim to develop a sensitive immunoassay for ovarian cancer detection that has linearity over a broad range, we hereby report a dual gold nanostructure-based electrochemical immunosensor to detect ovarian cancer biomarker carcinoma antigen 125 (CA125) in serum. Gold nanorods (GNRs) are coated on indium tin oxide (ITO) and used as working electrode after immobilizing capture anti-CA125 on it. Second, gold nanoparticles (GNPs) tagged with cadmium ion (Cd2+) and another CA125 antibody is used as a probe for signal generation. A sandwich between gold nanorod-modified working electrode and GNP-based probe is formed through CA125 antigen. Direct detection of probe bound on the surface of immunosensor was done by differential pulse voltammetry (DPV) and the peak signals were directly proportional to the CA125 antigen concentration. The developed sensor has shown a detection limit of 3.4 U mL−1 with a broad linear detection range of 20–100 U mL−1. The immunosensor is stable, reproducible and has a good correlation coefficient of 0.97 for the clinical serum samples tested with the developed immunosensor and enzyme-linked immunosorbent assay (ELISA). It has the potential to detect CA125 in clinical samples which show abnormally high or low levels of CA125 in serum.
KeywordsCA125 Gold nanorods Gold nanoparticles Electrochemical immunosensor
We gratefully acknowledge Director of MNNIT Allahabad for providing necessary research facilities, Sophisticated Analysis Instrumentation Facility, Panjab University, Chandigarh for TEM facility, Centre for Interdisciplinary Research (CIR), MNNIT, Allahabad for electrochemical workstation facility and Design and Innovation Centre (DIC), Ministry of Human Resource and Development (MHRD), New Delhi for their kind support. The authors also thank sincerely to Dr. Manisha Sachan, Assistant Professor, Department of Biotechnology, MNNIT Allahabad and Kings George Medical University (KGMU, Lucknow, India) for their generous effort in providing serum samples of ovarian cancer patients.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
Authors have no conflict of interests.
- Gong Z, Karandikar S, Zhang X, Kotipalli V, Lvov Y, Que L (2010) Composite nanomaterial thin film-based biosensors. In: Sensors 2010 IEEE Sensors pp. 29–32Google Scholar
- Kang JO, Hudak WA, Keller N (1988) Enzyme-linked immunosorbent assay of CA-125 in serum of patients with endometriosis: efficacy in diagnosis. Clin Chem 34:1983–1986Google Scholar
- Klapková E, Průša R, Kukačka J, Kotaška K, Škapa Klin P (2007) Unexpected high serum level of CA 125 in male patient suffering from metastatic papillary carcinoma: a case report. Biochem Metab 15:155–156Google Scholar
- Li X, Wu X, Ni Y (1996) Clinical determination of tumor markers. People’s Healthy Press, BeijingGoogle Scholar
- Reinsberg J, Schultes B, Wagner U, Krebs D (1993) Monitoring cancer antigen 125 in serum of ovarian cancer patients after administration of 131I-labeled F(ab’)2 fragments of OC125 antibody. Clin Chem 39:891–896Google Scholar
- Ryder KW, Oei TO, Hull MT, Sample MM (1988) An enzyme immunoassay procedure for cancer antigen 125 evaluated. Clin Chem 34:2513–2516Google Scholar
- Wu JT, Miya T, Knight JA, Knight DP (1988) Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen. Clin Chem 34:1853–1857Google Scholar
- Zhou C, Liu D, Xu L. Li Q, Song J, Xu S, Xing R, Song H (2015) A sensitive label–free amperometric immunosensor for alpha-fetoprotein based on gold nanorods with different aspect ratio. Sci Rep 5:1–7Google Scholar